RBC Capital raises Hinge Health price target to $75
RBC Capital analyst Rishi Jaluria maintained an Outperform rating on Hinge Health and raised the price target to $75 from $65, reflecting a positive outlook on the company's growth.
*this image is generated using AI for illustrative purposes only.
RBC Capital analyst Rishi Jaluria has maintained an Outperform rating on Hinge Health (NYSE: HNGE) and raised the price target to $75 from $65. The revised target reflects increased confidence in the company's market position and growth trajectory.
The decision to upgrade the price target underscores the firm's positive outlook on Hinge Health's operational performance. The previous target of $65 has been surpassed by the new valuation of $75, signaling a stronger bullish stance.
Analyst Rating and Price Target
The following table outlines the revised rating and price target details:
| Metric | Value |
|---|---|
| Rating | Outperform |
| Previous Price Target | $65 |
| New Price Target | $75 |
Hinge Health continues to be viewed favorably by RBC Capital, with the Outperform rating indicating expectations for the stock to outperform the market average.
What specific operational metrics or milestones is Hinge Health expected to achieve to justify the increased price target?
How might competitors respond to Hinge Health's strengthened market position, and could this impact its growth trajectory?
What are the potential risks or market conditions that could hinder Hinge Health from reaching the $75 price target?
15
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
